Coherus BioSciences (CHRS, Financial) has finalized the sale of its UDENYCA franchise to Intas Pharmaceuticals, completing a transaction initially announced in December 2024. The deal is valued at up to $558.4 million. As part of the agreement, Coherus received an upfront payment of $483.4 million, which includes $118.4 million for UDENYCA inventory.
The transaction officially closed on April 11, 2025, allowing Coherus the opportunity to gain an additional $75 million through milestone payments, contingent upon Intas reaching specified net sales thresholds for UDENYCA.
Upon the closing of this deal, Intas acquired key assets associated with the UDENYCA franchise, including the pre-filled syringe, autoinjector, and ONBODY device. Additionally, Intas assumed certain liabilities as part of the purchase agreement. The U.S. operations for UDENYCA are now managed by Accord BioPharma, Intas Pharmaceuticals' U.S. division specializing in oncology, immunology, and critical care therapies.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 4 analysts, the average target price for Coherus BioSciences Inc (CHRS, Financial) is $5.38 with a high estimate of $7.00 and a low estimate of $1.50. The average target implies an upside of 543.02% from the current price of $0.84. More detailed estimate data can be found on the Coherus BioSciences Inc (CHRS) Forecast page.
Based on the consensus recommendation from 5 brokerage firms, Coherus BioSciences Inc's (CHRS, Financial) average brokerage recommendation is currently 2.0, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
Based on GuruFocus estimates, the estimated GF Value for Coherus BioSciences Inc (CHRS, Financial) in one year is $1.63, suggesting a upside of 95% from the current price of $0.8359. GF Value is GuruFocus' estimate of the fair value that the stock should be traded at. It is calculated based on the historical multiples the stock has traded at previously, as well as past business growth and the future estimates of the business' performance. More detailed data can be found on the Coherus BioSciences Inc (CHRS) Summary page.
